Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-Controlled Phase II Trial

Next Previous
X
Search
Trial Profile

AXIS 2: AX200 for the Treatment of Ischemic Stroke - A Multinational, Multicenter, Randomized, Doubleblind, Placebo-Controlled Phase II Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Filgrastim (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms AXIS-2
  • Sponsors SYGNIS Bioscience GmbH

    • Most Recent Events

    • 19 Mar 2021 Results (n=259) of retrospective study assessing association of these imaging markers with functional outcome after acute ischemic stroke from patients enrolled in the AXIS-2 trial presented at the International Stroke Conference 2021
    • 28 Jan 2021 Results(n=259) of post hoc, exploratory and retrospective analysis , investigating association between imaging markers of brain frailty with functional outcome after acute ischemic stroke, published in the Stroke
    • 14 Apr 2012 Planned number of patients changed from 328 to 350 as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top